influenza
pneumonia
remain
major
caus
morbid
mortal
worldwid
airway
epitheli
cell
first
line
defens
viral
infect
lung
instrument
coordin
earli
inflamm
lead
adapt
immun
respons
ifn
gamma
induc
kda
protein
nonelr
cxc
chemokin
potent
biolog
effect
includ
monocyt
stimul
natur
killer
activ
cell
migrat
modul
adhes
molecul
express
inhibit
angiogenesi
well
antimicrobi
effect
high
concentr
role
viral
pneumonia
thoroughli
character
evid
suggest
import
migrat
nk
cell
macrophag
cell
neutrophil
plasmacytoid
dendrit
cell
lung
mous
model
rsv
infect
antibodymedi
neutral
result
signific
increas
diseas
symptom
includ
impair
viral
clearanc
reduc
pulmonari
dendrit
cell
number
matur
reduct
viral
specif
cell
synergist
upregul
describ
vitro
sever
cell
type
respons
differ
proinflammatori
molecul
alway
conjunct
ifn
ifn
induc
synergist
level
human
endotheli
cell
line
via
erk
depend
pathway
ifn
human
intestin
epitheli
cell
line
pdgf
ifn
blood
deriv
macrophag
ifn
primari
human
airway
smooth
muscl
cell
gastric
epitheli
cell
prolactin
ifn
well
substanc
p
ifn
human
keratinocyt
hyaluronan
fragment
ifn
mous
macrophag
interestingli
synergist
induct
describ
ifn
conjunct
human
astrocyt
macrophag
thought
play
role
hiv
induc
encephalopathi
mark
varieti
proinflammatori
molecul
elicit
synergist
respons
wide
varieti
cell
type
indic
highli
conserv
like
biolog
import
cellular
respons
howev
synergist
induct
respons
influenza
ifn
airway
epitheli
cell
previous
report
studi
demonstr
synergist
induct
well
differenti
primari
human
bronchial
epitheli
hbe
cell
follow
influenza
viru
infect
treatment
ifn
demonstr
synergi
mediat
interact
dsrna
intermedi
viral
replic
ifn
vitro
vivo
followup
mechanist
studi
synerg
found
transcript
regul
demonstr
chimer
promot
report
gene
assay
addit
depend
ifnar
pathway
neither
neutral
antibodi
ifnar
ifnar
defici
affect
synerg
final
appear
mediat
synerg
human
bronchial
tissu
purchas
commerci
sourc
nation
diseas
research
interchang
philadelphia
pa
describ
tissu
patient
diagnos
lungrel
diseas
use
lung
either
autopsi
leftov
reject
transplant
sent
us
arbitrari
numer
code
ident
link
actual
patient
identifi
proteasedissoci
hbe
cell
plate
chamber
corn
maintain
immers
cultur
condit
reach
confluenc
transfer
airliquid
interfac
ali
cultur
condit
airliquid
interfac
cell
maintain
ham
addit
transferrin
insulin
cholera
toxin
ngml
epiderm
growth
factor
ngml
dexamethason
bovin
hypothalamu
extract
bsa
mgml
alltransretino
acid
nm
cell
maintain
ali
day
place
basal
media
devoid
addit
except
retino
acid
overnight
prior
experi
recombin
ifn
purchas
r
system
synthet
doubl
strand
ds
rna
ie
poli
c
emd
bioscienc
ifn
use
ngml
poli
c
neutral
antibodi
ifnar
obtain
us
biolog
use
kinas
jak
inhibitor
purchas
emd
bioscienc
use
influenza
infect
cell
infect
influenza
viru
strain
mem
hau
vivo
studi
balbc
mice
purchas
charl
river
laboratori
use
week
age
intratrach
instil
primari
airway
epitheli
cell
cultur
ifnar
null
mice
kind
gift
dr
nicol
baumgarth
ucd
wildtyp
control
mice
mice
use
week
age
protocol
describ
approv
univers
california
davi
univers
arizona
respons
proper
care
use
experiment
anim
protocol
perform
describ
previous
briefli
time
necropsi
chest
cervic
region
expos
small
punctur
place
proxim
trachea
allow
cannul
steril
mm
polyethylen
tube
intramed
clay
adam
secur
place
silk
sutur
loos
sutur
place
distal
end
trachea
proxim
carina
trachea
dissect
free
immedi
place
dmem
trachea
gentli
inflat
proteas
tracheal
cannula
tighten
distal
sutur
dissoci
epitheli
cell
gentli
harvest
inject
millilit
cell
cultur
media
trachea
mte
cell
trachea
pool
resuspend
cell
cultur
media
prior
plate
chamber
corn
coat
advanc
biomatrix
mte
cell
maintain
submerg
condit
confluent
time
kept
airliquid
interfac
condit
one
week
presenc
nm
retino
acid
experi
mte
cell
treat
ng
recombin
murin
ifn
r
system
andor
dsrna
hour
protocol
perform
describ
previous
briefli
balbc
mice
anesthet
isofloran
dorsal
recumb
tongu
gentli
pull
pipett
tip
gentli
insert
laryng
region
oral
caviti
mg
dsrna
andor
recombin
murin
ifn
lp
free
pb
deposit
breath
lp
free
pb
use
control
mice
kept
upright
posit
recoveri
anesthesia
twenti
four
hour
later
mice
euthan
lung
lavag
ml
pb
lung
flash
frozen
liquid
nitrogen
subsequ
rna
isol
total
rna
extract
reagent
invitrogen
cdna
gener
equal
amount
rna
per
reaction
moloney
murin
leukemia
virusrevers
transcriptas
appli
biosystem
use
random
hexam
invitrogen
sybr
green
master
mix
roch
appli
scienc
detect
system
appli
biosystem
use
follow
manufactur
protocol
realtim
pcr
analysi
rel
mrna
amount
sampl
calcul
base
threshold
cycl
ct
comparison
ct
housekeep
gene
beta
actin
glyceraldehyd
dehydrogenas
gapdh
result
present
ct
ct
housekeep
gene
fold
induct
control
condit
puriti
amplifi
product
determin
singl
peak
dissoci
curv
throughout
studi
observ
fluctuat
ct
valu
housekeep
gene
differ
treatment
condit
primer
human
murin
purchas
sa
bioscienc
primer
sequenc
human
beta
actin
follow
forward
tgtgtccgtcgtggatctga
revers
cctgcttcaccaccttcttgat
primer
sequenc
murin
gapdh
follow
forward
tcctccacctttgacgctg
revers
accaccctgttgctgtagcc
prepar
collect
condit
media
primari
human
airway
epitheli
cell
cell
wash
twice
steril
pb
fresh
media
contain
ifn
andor
poli
c
place
basal
media
place
apic
follow
hour
incub
media
harvest
centrifug
remov
cellular
debri
store
bronchoalveolar
lavag
fluid
use
murin
elisa
commerci
avail
elisa
kit
use
accord
manufactur
direct
r
system
result
normal
amount
condit
media
lavag
fluid
express
ngml
pgml
construct
contain
bp
upstream
transcript
start
site
clone
luciferas
report
vector
promega
construct
confirm
dna
sequenc
earli
differenti
hbe
cell
day
transfect
promoterluciferas
construct
prltk
use
lipofectamin
invitrogen
accord
manufactur
specif
prltk
use
intern
control
normal
transfect
effici
empti
vector
basic
use
neg
control
brief
cell
plate
onto
well
plate
confluenc
next
day
cell
wash
twice
optimem
invitrogen
transfect
cell
incub
mixtur
dna
construct
lipofectamin
optimem
hour
time
cell
cultur
media
also
ad
cell
transfect
cultur
treat
ngml
ifn
andor
poli
c
hour
dual
luciferas
report
assay
kit
promega
use
follow
manufactur
protocol
transfect
rel
firefli
luciferas
activ
normal
renilla
luciferas
activ
mous
monoclon
antibodi
chain
human
alpha
beta
omega
interferon
receptor
ifnar
ad
cultur
media
cell
hour
prior
start
experi
antibodi
previous
document
neutral
extracellular
domain
human
type
interferon
receptor
high
affin
dose
use
studi
ifn
andor
poli
c
ad
cultur
media
follow
preincub
period
ifnra
antibodi
still
present
mous
igg
use
control
follow
hour
incub
rna
isol
qpcr
perform
previous
describ
data
express
mean
se
experi
conduct
triplic
least
three
independ
cultur
group
differ
calcul
use
analysi
varianc
anova
follow
bonferroni
multipl
comparison
test
differ
consid
signific
p
valu
less
shown
fig
well
differenti
hbe
cell
demonstr
signific
synergist
induct
mrna
follow
infect
mem
influenza
viru
treatment
ifn
induct
also
significantli
elev
follow
combin
treatment
mem
ifn
treatment
compar
treatment
ifn
alon
consist
potenti
protein
product
combin
treatment
detect
cell
cultur
supernat
hbe
cell
fig
apic
releas
enhanc
treatment
condit
pronounc
level
detect
combin
mem
infect
ifn
treatment
fig
interestingli
signific
level
also
releas
basal
except
much
lower
apic
secret
result
demonstr
influenza
viru
combin
ifn
synergist
induc
mrna
protein
product
primari
human
airway
epitheli
cell
viral
replic
intermediatedoubl
strand
ds
rna
shown
mediat
mani
influenza
induc
phenotyp
examin
possibl
dsrna
could
synerg
ifn
induct
shown
fig
hbe
cell
demonstr
synergist
induct
mrna
time
depend
manner
start
earli
hour
treatment
treatment
ifn
dsrna
result
signific
synergist
induct
mrna
level
time
point
combin
treatment
hour
result
fold
induct
mrna
consist
fig
demonstr
potenti
protein
cell
cultur
supernat
hbe
cell
treat
hour
apic
releas
enhanc
treatment
condit
pronounc
level
detect
combin
ifn
dsrna
treatment
signific
level
also
releas
basal
although
level
much
lower
apic
secret
result
suggest
synergi
influenza
infect
ifn
treatment
may
caus
interact
dsrna
ifn
signal
pathway
determin
whether
ifn
dsrna
synergist
induc
vivo
perform
intratrach
deliveri
ifn
dsrna
balbc
mice
examin
mrna
protein
level
shown
fig
dsrna
alon
induc
signific
increas
mrna
ifn
dsrna
treatment
togeth
synergist
induc
mrna
fold
mous
lung
likewis
fig
demonstr
signific
induct
protein
bronchoalveolar
lavag
fluid
treatment
dsrna
synergist
induct
follow
ifn
dsrna
treatment
result
demonstr
synergist
induct
mrna
protein
vivo
follow
ifn
dsrna
treatment
dsrna
known
induc
type
interferon
pathway
investig
involv
pathway
use
neutral
antibodi
human
ifnar
fig
demonstr
ifnar
neutral
antibodi
affect
synergist
induct
mrna
hbe
cell
although
repress
dsrnainduc
confirm
result
isol
mte
cell
ifnar
null
mice
complet
lack
ifnar
express
fig
demonstr
lack
ifnar
affect
synergist
induct
interestingli
induct
dsrna
alon
significantli
impair
mte
cell
ifnar
null
mice
compar
cell
wildtyp
mice
taken
togeth
result
demonstr
synergist
induct
mrna
independ
type
interferon
receptor
human
mous
airway
epitheli
cell
contrast
dsrnainduc
appear
depend
type
interferon
receptor
suggest
synergi
may
mediat
via
differ
pathway
rapid
elev
ifn
andor
dsrna
fig
test
possibl
synergi
occur
transcript
level
transient
transfect
hbe
cell
promoterluciferas
chimer
construct
contain
bp
upstream
regulatori
region
fig
demonstr
combin
treatment
ifn
dsrna
significantli
increas
luciferas
report
gene
activ
compar
treatment
ifn
dsrna
alon
result
support
synerg
occur
least
partial
direct
transcript
mechan
proxim
bp
region
promot
critic
induct
isr
site
present
clone
promot
region
test
stat
pathway
synerg
pathway
shown
respons
gene
express
inde
specif
inhibitor
target
kinas
either
upstream
kinas
jak
significantli
block
induct
ifn
dsrna
combin
treatment
fig
confirm
indispens
role
pathway
regul
express
signal
pathway
examin
treatment
ifn
dsrna
alon
found
induc
robust
degrad
surrog
activ
pathway
initi
reaction
catalyz
kinas
combin
treatment
result
much
greater
degrad
compar
singl
treatment
fig
contrast
despit
activ
treatment
synerg
observ
fig
therefor
synerg
ifn
dsrna
express
mediat
pathway
airway
epitheli
line
first
defens
respiratori
viral
infect
studi
seek
understand
modul
import
combin
effect
ifn
viral
infect
first
report
document
observ
mechan
underli
synerg
ifn
viral
infect
dsrna
treatment
airway
epitheli
cell
ifn
type
ii
interferon
oftentim
elev
context
viral
infect
gener
accept
direct
innat
antivir
defens
mediat
type
ifn
inde
other
shown
dsrna
viru
induc
epitheli
deriv
type
ifn
play
critic
role
airway
antivir
defens
present
studi
demonstr
synergi
dsrna
ifn
signal
regul
interestingli
although
dsrnainduc
depend
type
ifn
pathway
synergi
dsrna
ifn
complet
independ
human
mous
epitheli
cell
lack
depend
due
remain
residu
ifnar
function
antibodi
neutral
assay
epitheli
cell
ifnar
defici
mice
use
fig
still
preserv
synergist
respons
despit
loss
entir
ifnar
express
thu
presenc
ifn
dsrna
viru
induc
signal
like
alter
emphas
import
studi
pathway
crosstalk
demonstr
present
studi
previou
studi
demonstr
ifn
conjunct
differ
proinflammatori
molecul
lead
synergist
dramat
induct
varieti
cell
type
includ
keratinocyt
macrophag
endotheli
cell
smooth
muscl
cell
sever
studi
demonstr
transcript
factor
involv
induct
varieti
system
contrast
studi
demonstr
induct
depend
isr
site
promot
region
kanda
cowork
found
substanc
p
ifn
induc
synerg
human
keratinocyt
depend
isr
site
two
site
promot
locat
transcript
start
site
addit
majumd
cowork
found
evid
ifn
tnf
act
synergi
via
complex
bind
isr
site
promot
human
fibrosarcoma
line
evid
similar
synerg
occur
transcript
level
mous
cell
demonstr
small
number
vitro
studi
use
murin
fibroblast
nih
cell
line
ohmoir
cowork
establish
isr
site
one
two
site
bp
fragment
flank
transcript
start
site
murin
gene
critic
ifn
tnf
induc
synergi
studi
extend
studi
airway
epitheli
system
context
viral
infect
result
appar
support
import
present
studi
demonstr
signific
contribut
epitheli
cell
consist
emerg
role
activ
defens
cell
respiratori
viral
infect
secret
hbe
cell
appear
polar
treatment
ifn
dsrna
combin
treatment
result
progress
enhanc
secret
mainli
apic
surfac
contrast
basal
secret
protein
cultur
much
less
gradient
apic
basal
compart
may
import
implic
vivo
lead
enhanc
emigr
posit
effector
cell
primarili
cell
airway
epitheli
microenviron
although
dsrna
use
extens
synthet
dsrna
model
viral
infect
stabil
deriv
also
investig
clinic
use
immunomodulatori
agent
use
vaccin
adjuv
antivir
treatment
cancer
therapi
dsrna
use
studi
simul
viral
infect
import
note
also
involv
synergist
induct
airway
epitheli
cell
fact
could
import
consider
treatment
patient
preexist
diseas
ifn
part
pathogenesi
viral
infect
summari
demonstr
ifn
influenza
viru
synergist
induc
human
airway
epitheli
cell
synerg
like
mediat
dsrnainduc
signal
vitro
vivo
independ
type
interferon
receptor
pathway
furthermor
demonstr
bp
proxim
region
promot
play
critic
role
regul
synergist
induct
region
promot
contain
punit
isr
nfkb
transcript
factor
bind
site
therefor
studi
carri
demonstr
involv
nfkb
synerg
capac
airway
epitheli
cell
markedli
upregul
like
import
consequ
cell
nk
cell
migrat
airway
epitheli
microenviron
follow
influenza
viru
infect
